TickerTalks
Browse all tickers →
TickerTalks›$MAZE
MAMAZE

Maze Therapeutics, Inc.

$MAZE·$1.6B·Biotechnology·Healthcare
$25.87-1.3%YTD-35.9%1Y+0.1%
Price updated 6m ago
MAMAZE
$MAZEMaze Therapeutics, Inc.
$25.87-1.28%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $MAZE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MAZE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeWinding up for a moveAI verdict · as of 2026-09-25

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Maze Therapeutics is -36% YTD as APOL1 kidney disease and metabolic pipeline advances — but multiple officers sold ~$2M+ across Sept 3-8.

Maze Therapeutics is a clinical-stage biotech developing MZE829 (APOL1 kidney disease, Phase II) and MZE782 (metabolic disease) — a small molecule precision-medicine franchise where the science is advancing but insiders are actively selling.

  • Q2 2026 revenue was zero (Q1 recognized a $20M collaboration milestone) with quarterly cash burn of $15-40M and EPS -$0.45 to -$0.87; the operating base is the clinical-stage investment cadence.
  • Sept 3-8 insider disposition cluster: Coloma (officer/director) sold ~$1.5M across three tranches, Bernstein $524K, Dandekar $169K, Phillips $105K — coordinated post-earnings selling by multiple named executives.
  • Sept 24 defenseworld notes shares gapping up; Sept 7 disclosed Frazier Life Sciences holds MAZE as its 8th largest position — real specialist-investor validation; Sept 10 Citi Biopharma Back to School Summit presentation.

Next earnings Nov 5 (Street -$0.79 EPS). Analysts model 2026 revenue $20M easing to $13.9M in 2027 and $13.0M in 2028 with losses widening — the sell-side is modeling continued heavy investment before commercial payoff. What matters: MZE829 Phase II data readout timing, MZE782 development pace, cash runway commentary, and continued Coloma / officer disposition patterns. Stock at 13% of 52-week range and 22% below 200-day — deep drawdown.

What to watch: Q3 earnings Nov 5 (-$0.79 EPS estimate). MZE829 Phase II data readout timing, MZE782 development pace, cash runway commentary, and continued Coloma / officer disposition patterns.

On the calendar: 2026-11-05 — Q3 2026 earnings

Read the AI verdict on $MAZE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing small molecule precision medicines targeting kidney disease and metabolic disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MAZE.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-28.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-7.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
78.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-34.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
95.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.76$-0.72-6.0%
Q1 2026May 12, 2026$-0.45$-0.43-4.7%
Q4 2025Mar 25, 2026$-0.65$-0.73+11.0%
Q3 2025Nov 6, 2025$-0.66$-0.74+10.8%
Next earningsThu, Nov 5·consensus EPS $-0.79

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.76$-15.2M
Q1 FY26$20.0M—97.8%-133%$-0.45$-39.2M
Q4 FY25$0———$-0.87$-27.8M
Q3 FY25$0-100.0%——$-0.66$-24.7M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$20.0M$20.0M – $20.0M-$2.76-$2.98 – -$2.109
FY27$13.9M$13.9M – $13.9M-$3.21-$4.23 – -$2.427
FY28$13.0M$13.0M – $13.0M-$3.57-$6.03 – -$2.7810
FY29$51.0M$51.0M – $51.0M-$3.83-$3.83 – -$3.835
FY30$212.7M$212.7M – $212.7M-$2.58-$2.58 – -$2.585

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-21.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 16.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 4Harold BernsteinPresident9.7K sh$255KSellSep 3Phillips CourtneyGC and Corp. Secretary2.0K sh$52KSellSep 3Jason V ColomaCEO11.4K sh$297KSellSep 3Harold BernsteinPresident5.2K sh$135KSellSep 3Atul DandekarCSBO3.2K sh$84KSellSep 2Jason V ColomaCEO11.2K sh$297KSellSep 2Phillips CourtneyGC and Corp. Secretary2.0K sh$52KSellSep 2Atul DandekarCSBO3.2K sh$84KSellSep 2Harold BernsteinPresident5.1K sh$135KSellSep 1Jason V ColomaCEO34.5K sh$907K
1–10 of 15
+ 10 other (8 exempts · 2 awards) in window

See when $MAZE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 173
3New insider — initial holdingsAug 173
8-KOfficer or director changeAug 178-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
8-KOfficer or director changeMay 228-K — Item 5.02: Officer or director change
424B5Prospectus supplement (offering)Apr 22424B5
3New insider — initial holdingsMar 313
+ 14 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Time to Buy?defenseworld.net·2d agoMaze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000fool.com·14d agoMaze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com·15d agoMaze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Positiondefenseworld.net·19d agoMaze Therapeutics to Participate in Three Upcoming Investor Conferencesglobenewswire.com·23d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $MAZE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport